Fig. 1

Principal component analysis of rituximab induction studies. 1: DE-Bad-Bramstedt [14]; 2: US-Cleveland [19]; 3: DE-Freiburg [24]; 4: DE-Munich [18]; 5: SE-Gothenburg; [15]; 6: SE-Stockholm [16]; 7: RAVE study [4]; 8: US-Rochester [11], 9: SE-Linköping [10]; 10: NO-Tromsø [6]. Age: age in years; BVAS: Birmingham Vasculitis Activity Score; CYC: proportion of patients exposed to cyclophosphamide; Kidney: proportion of patients with kidney involvement; Lung: proportion of patients with lung involvement; Men: proportion of men in studies; N: number of patients in studies; PR3: proportion of patients who are PR3-ANCA positive; RTX_1gx2: proportion of patients who received rituximab 1g twice given one fortnight apart (rheumatoid arthritis protocol)